Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BRB-002
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bitterroot Bio Reports Safety Data from Phase 1 BRB-002 Study in Healthy Volunteers
Details : BRB-002 is a novel protein therapy targeting CD47 that is being investigated as a potential treatment option for patients with atherosclerotic cardiovascular disease (ASCVD).
Product Name : BRB-002
Product Type : Protein
Upfront Cash : Inapplicable
January 08, 2025
Lead Product(s) : BRB-002
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BRB-002
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bitterroot Completes Phase 1 Enrollment for BRB-002 in Healthy Volunteers
Details : BRB-002 is a novel protein therapy targeting CD47 that is being investigated as a potential treatment option for patients with atherosclerotic cardiovascular disease (ASCVD).
Product Name : BRB-002
Product Type : Protein
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : BRB-002
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BRB-002
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bitterroot Bio Doses First Participants in Phase 1, First-in-Human Study of BRB-002
Details : BRB-002 is a novel protein therapy targeting CD47 that is being investigated as a potential treatment option for patients with atherosclerotic cardiovascular disease (ASCVD).
Product Name : BRB-002
Product Type : Protein
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : BRB-002
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : Biotheus
Deal Size : Undisclosed
Deal Type : Collaboration
Bitterroot and Biotheus Collaborate to Develop Bispecific Proteins in Cardio-Immunology
Details : This collaboration will focus on discovering and developing medicines that may offer new hope for patients suffering from atherosclerosis and other life-threatening cardiovascular conditions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 26, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : Biotheus
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Arch Ventures
Deal Size : $145.0 million
Deal Type : Series A Financing
Details : The net proceeds will be used to develop transformative medicines in cardio-immunology, including company’s lead program targeting the CD47/SIRPα pathway, designed to address the underlying dysfunction that contributes to atherosclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Arch Ventures
Deal Size : $145.0 million
Deal Type : Series A Financing